Biopharmaceutical company
Appears in 1 story
Developing amezosvatein shingles vaccine with superior tolerability profile, Phase 2 extension ongoing
Sanofi dropped $2.2 billion on December 24, 2025 to acquire Dynavax, a California biotech with a two-dose hepatitis B vaccine and a shingles vaccine in development. The 39% premium signals desperation in a market projected to hit $37.2 billion by 2033, driven by aging populations; the deal is expected to close in Q1 2026 pending Hart-Scott-Rodino antitrust clearance.[1] By 2050, 2.1 billion people will be over 60, triple the population over 80.
Updated May 16
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
